MiSight® 1 day - The world’s only myopia management lens supported by a 7 year clinical trial1,2,3
MiSight® 1 day contact lenses with ActivControl® Technology are dual-purpose: they provide clear vision and help to control the worsening of myopia1
MiSight® 1 day contact lenses are supported by rigorous scientific evidence from a 7 year clinical trial.1,2,3
MiSight® 1 day works for nearly all children with myopia2*
The majority of children fit with MiSight® 1 day do not need a stronger prescription by their next annual eye exam1†
At all observed ages (8-17), MiSight® 1 day cut the worsening of myopia by approximately 50%4‡
Even older children starting with MiSight® 1 day have their myopia progression cut by half.4§
MiSight® 1 day works for as long as the child wears them4‖
MiSight® 1 day is the only soft contact lens studied post-treatment. Other interventions, such as atropine, have been shown to produce a rebound effect 3,6¶#
MiSight® 1 day contact lenses are child-friendly and easy-to-use1
MiSight® 1 day covers nearly 100% of spherical prescriptions for children with myopia.10Δ
 |
Sphere powers -0.25 to -6.00 (0.25 steps) -6.50 to -10.00 (0.50 steps) |
*90% of myopic eyes respond to MiSight® 1 day treatment; ages 11-15 at start of wear, n=90.
†No clinically meaningful change in refractive error (<0.25D from baseline) in years 1-3 of the MiSight® 1 day clinical study.
‡ Using measured and modeled data, pooled across ages (8-17), MiSight® 1 day slowed myopia progression by an average of approximately 50%
§ Children ages 8 to 15 when starting MiSight 1 day treatment experienced a slowing of myopia progression.
‖ Children with myopia fit with MiSight® 1 day contact lenses ages 8-15 continued to experience slowed myopia progression as long as they remained wearing the lenses as prescribed.
¶12 months post-treatment, evidence indicates that no accumulated myopia control benefits were lost following 3 or 6-years of MiSight® 1 day wear (on average, for children aged 8-15 at start of wear). Instead, eye growth reverted to expected, age-normal rates.
# Atropine and orthokeratology studies have shown post-treatment rebound effect, and there’s currently no post-treatment evidence for spectacles or other soft contact lenses.
Δ Includes prescriptions up to 0.75DC.
1. Chamberlain P et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019; 96(8): 556-567.
2. Chamberlain P et al. Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci. 2022; 99(3): 204-212.
3. Chamberlain P et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7-year findings. Optom Vis Sci. 2021; 98(E-abstract): 210049.
4. Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. Invest. Ophthalmol. Vis. Sci. 2021; 62(8): 2333.
5. Arumugam B et al. The Effects of Age on Myopia Progression with DualFocus and Single Vision Daily Disposable Contact Lenses. Optom Vis Sci. 2020; 97(E-abtract): 205340.
6. Hammond D et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. Optom Vis Sci. 2021; 98(E-abstract): 215130.
7. Chamberlain P et al. Myopia Progression in Children wearing Dual-Focus Contact Lenses: 6-year findings. Optom Vis Sci. 2020; 97(E-abstract): 200038.
8. Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. Cont Lens Anterior Eye. 2021; 44(4): 101391.
9. Sulley A et al. Wearer experience and subjective responses with dual focus compared to spherical, single vision soft contact lenses in children. Optom Vis Sci. 2019; 96(E-abstract): 195252.
10. CVI data on file, 2022. SERE coverage of childhood myopia prescriptions with MiSight® 1 day for 104,810 eyes in Asia (China, Korea) and 116,336 eyes in Europe and USA aged 8-18 years.
Product Details
-6.50 to -10.00 (0.50D steps)
